Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 DCF chemoradiotherapy for locally advanced thoracic esophageal cancer invading the aorta or trachea
jRCTs051190058Phase 2Active, not recruiting
- Start
- Sep 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Adverse effect. Started Sep 2019; status: active, not recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs051190058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190058.